
    
      This study is comprised of a 4-week pre-treatment screening period, 24-week treatment period
      and 4-week post-treatment follow-up period. The 24-week treatment period consists of a
      12-week double-blind (DB) part and 12-week open-label extension (OLE) part and each part
      includes a 2 week Low dose Period and a 10-week High-dose Period.
    
  